PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist originally developed from the peptide melanotan II. Unlike medications such as sildenafil or tadalafil, which improve genital blood flow through vascular mechanisms, PT-141 works primarily within the central nervous system by activating melanocortin receptors involved in sexual desire and arousal.
The FDA-approved form of bremelanotide is marketed as Vyleesi® and is approved only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
PT-141 primarily activates melanocortin-4 receptors (MC4R) and, to a lesser extent, melanocortin-3 receptors (MC3R) in the brain.
This may result in:
Potential benefits may include:
Potential side effects include:
PT-141 should generally be avoided in individuals with:
Caution is also appropriate in patients taking oral medications that require rapid absorption because bremelanotide may delay gastric emptying.
Bremelanotide/Vyleesi® is FDA-approved for:
It is not FDA-approved for:
Human Studies
PT-141 has been studied in humans for female hypoactive sexual desire disorder, female sexual arousal disorder, erectile dysfunction, and sexual arousal physiology.
Two large Phase III randomized trials demonstrated improvements in sexual desire and reductions in distress in premenopausal women with acquired, generalized HSDD, leading to FDA approval of Vyleesi®.
Animal & Preclinical Studies
Animal studies have shown that PT-141 may:
The information provided on this page is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or treatment.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, outdated information, or incomplete interpretations of the available scientific literature.
PT-141/bremelanotide is FDA-approved only as Vyleesi® for acquired, generalized HSDD in premenopausal women. Other uses are not FDA-approved. Individual results vary, and no specific outcome or benefit can be guaranteed.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# NAD+ (Nicotinamide Adenine Dinucleotide)